HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation.

AbstractPURPOSE:
The aim of this study was to determine whether the presence of symptoms would aid in the detection of valvular heart disease (VHD) in those exposed to pergolide.
METHODS:
Utilizing a prospective, cross-sectional study design, patients with an exposure to pergolide were asked regarding the presence or absence of chest pain, shortness of breath or lower extremity edema through a questionnaire. Echocardiograms were obtained on the same day as the questionnaire and were blinded to all staff involved in the study. The sensitivity, specificity, positive and negative predictive value of the reported symptoms towards the outcome moderate or severe valvular regurgitation were obtained. Using the area under the receiver-operating characteristic curve, we also ascertained whether a relationship existed between symptoms, pergolide dose and presence of VHD. To understand the associations between symptoms and echocardiographic covariates, a logistic regression analysis was performed adjusted for age and gender.
RESULTS:
The sensitivity, specificity, positive and negative predictive value of symptom presentation and total dose was sufficiently low that it did not aid in the determination whether significant valvular regurgitation was present. Multivariable analysis noted a significant association with indexed left atrial volume (p = 0.011), estimated pulmonary artery pressure (p = 0.047) and shortness of breath.
CONCLUSIONS:
The presence or absence of symptoms does not help guide whether valvular regurgitation is present or absent in individuals exposed to pergolide. Therefore, echocardiography is needed to confirm or refute pergolide-associated VHD.
AuthorsAshok Krishnaswami, Kathleen B Albers, Robin D Fross, James J Jang, Sarah B Berkheimer, Valerie C Kwai Ben, Stephen K Vandeneeden
JournalPharmacoepidemiology and drug safety (Pharmacoepidemiol Drug Saf) Vol. 21 Issue 3 Pg. 276-80 (Mar 2012) ISSN: 1099-1557 [Electronic] England
PMID22231899 (Publication Type: Journal Article)
CopyrightCopyright © 2012 John Wiley & Sons, Ltd.
Chemical References
  • Dopamine Agonists
  • Pergolide
Topics
  • Aged
  • California
  • Cross-Sectional Studies
  • Databases, Factual
  • Dopamine Agonists (administration & dosage, adverse effects, therapeutic use)
  • Dose-Response Relationship, Drug
  • Electrocardiography
  • Female
  • Heart Valve Diseases (chemically induced, diagnosis, epidemiology)
  • Humans
  • Logistic Models
  • Male
  • Multivariate Analysis
  • Pergolide (administration & dosage, adverse effects, therapeutic use)
  • Predictive Value of Tests
  • Prospective Studies
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: